Short Interest in Catheter Precision, Inc. (NYSEAMERICAN:VTAK) Decreases By 53.7%

Catheter Precision, Inc. (NYSEAMERICAN:VTAK) was the target of a large drop in short interest during the month of April. As of April 30th, there was short interest totaling 37,414 shares, a drop of 53.7% from the April 15th total of 80,782 shares. Based on an average trading volume of 137,830 shares, the days-to-cover ratio is presently 0.3 days. Approximately 1.5% of the company’s shares are sold short.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Catheter Precision stock. Millennium Management LLC acquired a new position in shares of Catheter Precision, Inc. (NYSEAMERICAN:VTAK) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 34,721 shares of the company’s stock, valued at approximately $64,000. Millennium Management LLC owned about 2.08% of Catheter Precision at the end of the most recent reporting period. Institutional investors own 20.34% of the company’s stock.

Catheter Precision Trading Down 1.4%

Catheter Precision stock traded down $0.01 during midday trading on Friday, hitting $0.76. 33,645 shares of the stock were exchanged, compared to its average volume of 783,306. The company has a fifty day simple moving average of $1.09 and a two-hundred day simple moving average of $1.69. Catheter Precision has a 52 week low of $0.76 and a 52 week high of $15.68. The stock has a market capitalization of $2.05 million, a PE ratio of -0.04 and a beta of -1.04. The company has a quick ratio of 0.08, a current ratio of 0.10 and a debt-to-equity ratio of 0.46.

About Catheter Precision

Catheter Precision, Inc (NYSE American: VTAK) is a medical device company specializing in the design, development and manufacture of catheter-based products for interventional cardiology and peripheral vascular procedures. The company’s core business centers on balloon catheter platforms, offering both standard and specialty catheter configurations that address applications ranging from percutaneous transluminal angioplasty (PTA) to percutaneous transluminal coronary angioplasty (PTCA). Catheter Precision’s product portfolio is engineered to meet diverse clinical needs, including high-pressure dilation, scored and cutting balloon therapies, and drug-coated balloon delivery.

All of Catheter Precision’s products are developed in its ISO 13485-certified, FDA-registered manufacturing facility in Bloomington, Minnesota.